Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Summary

This Phase I study is to determine the maximum tolerated fraction dose (MTD) for split-course hypo-CCRT following induction chemo-immunotherapy in LA-ESCC patients, to clarify the dosimetric advantage of split-course hypo-CCRT, and to investigate the treatment-related toxicities and quality of life of the new regimen.

Timeline

Start

2023-08-31

Primary completion

2025-10-30

Completion

2025-10-30

Publications

• Liu F, Wang D, Luo G, Zhang H, Liu Y, Zhang P, Xia B, SiTu Y, Wang M, Zhang D, Hu Y, Wang J, Qiu B, Liu H. Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study. EClinicalMedicine. 2026 Apr 17;95:103893. doi: 10.1016/j.eclinm.2026.103893. eCollection 2026 May.

Drugs

Indications